A prospective clinical trial was carried out to explore the hemostatic effect of Gongxueting Mixture on metrorrhagia and metrostaxis with blood stasis syndrome and its mechanism. Bleeding time and bleeding volume in 37 cases were detected before and after treatment to assay the hemostatic effect. Indexes of blood analysis, blood rheology, blood coagulation and prostaglandin in 8 cases were determined to study the mechanism. The results showed that Gongxueting Mixture shortened the menstrual period and regulated the volume of menses (P 0.05 ). It is concluded that Gongxueting Mixture is effective for metrorrhagia and metrostaxis with blood stasis syndrome (the total effective rate being 91.89% ), and enhancement of platelet aggregation, promotion of fibrinolytic activity and regulation of prostaglandin release may be its hemostatic mechanism.

Objective To observe the effect of dihydromyricetin of ampelopsis grossedentata on lipid metabolism and antioxidation in atherosclerosis (AS) rats. Methods Sixty Wistar rats were randomly divided into five groups (n = 12 each):normal control group, model control group, positive control group, high dose dihydromyricetin group (40 mg·kg-1 ) and low dose dihydromyricetin group (10 mg·kg-1 ). Except normal control group, rats in the other groups were injected with a single dose of vitamin D3(600 000 U·kg-1 ) and loaded with high fat diet to establish AS model. Simvastatin (5 mg·kg-1 ) was intragastrically administered to positive control group. High and low dose dihydromyricetin groups received intragastric administration of 40 and 10 mg·kg-1 dihydromyricetin, respectively. Equal volume of purified water was given to normal and model group. After 24 weeks of administration, serum levels of lipids, activities of superoxide-dismutase (SOD) and malonicdialdehyde (MAD) were determined. Results As compared with model control group, triglycerides (TG) of high and low dose dihydromyricetin groups was decreased [(191. 65±101. 10) vs. (111. 10±29. 29) and (120. 55±38. 12) mg·L-1 , respectively], total cholesterol (TC) was decreased [(151. 64±33. 62) vs. (148. 49±30. 14) and (118. 90±27. 38) mg·L-1 ], and high density lipoprotein cholesterol (HDL-C) was increased [(1. 29±0. 68) vs. (2. 10±0. 70) and (1. 62±0. 61) mmol·L-1 ], low density lipoprotein cholesterol (LDL-C) was decreased [(5. 01±1. 33) vs. (3. 97±0. 78) and (4. 28±0. 79) mmol·L-1 ], activity of SOD was increased [(141. 03±42. 52) vs. (187. 97±42. 08) and (150. 99±46. 17) U·mL-1 ], and MDA was decreased [(20. 51±3. 81) vs. (17. 64±1. 54) and (18. 52± 3. 42) nmol·mL-1 ], with significant differences (P<0. 05, P<0. 01). Conclusion Dihydromyricetin can reduce the level of serum lipid, improve antioxidation activity, and has therapeutic effect for atherosclerosis.